This episode focuses on the critical phase of post-market drug surveillance, including post-approval commitments and Phase 4 studies. We discuss the shift in focus from early-phase clinical trials, which prioritize safety and initial efficacy, to long-term safety and effectiveness in a much wider patient population. We explain the concept of surrogate endpoints and how they can be used to support accelerated approvals, emphasizing the importance of post-marketing studies to confirm clinical benefit. We also delve into the complexities of real-world drug use and the challenges of monitoring adverse events and refining our understanding of a drug's safety profile in diverse populations. Join us as we explore the ongoing monitoring and data collection that occur after a drug is approved.

This episode further explores the importance of post-mar ...